
Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideoOut 100
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
Is it possible for treatment-naive HIVers to begin antiretroviral therapy with only two boosted protease inhibitors and no other anti-HIV medications? That's precisely what researchers in France recently aimed to discover in their study of 61 HIVers who began therapy with either Norvir-boosted Lexiva plus Reyataz or Norvir-boosted Invirase plus Reyataz. The results, unfortunately, were not as robust as the researchers had hoped. Although many of the study participants with viral loads above 50,000 did reduce HIV levels to below 50 copies after 16 weeks of treatment (40% of those taking Lexiva/Reyataz and 42% of those taking Invirase/Reyataz), the percentages were far below that seen after 16 weeks with multiclass antiretroviral combinations. "[Norvir]-boosted dual protease inhibitor regimens targeting only one step of viral replication were insufficient to rapidly suppress plasma HIV RNA ' in antiretroviral-naive patients with a high viral load at baseline," the researchers conclude in the Journal of Antimicrobial Chemotherapy.
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Plus: Featured Video
Latest Stories
7 Uplifting Films To Celebrate Trans Awareness Week & Where To Stream Them
November 17 2023 10:25 AM
Out's Deal Guide: Grab Your 50% Off Amazon Fire Tablets & More Recommended Deals on Amazon Today!
November 03 2023 3:44 PM
Unlock Massive Savings at 'The Holiday Shop': Amazon's Hottest Deals of the Season Await!
November 02 2023 2:17 PM
Dianne Feinstein’s Commitment to People Living With HIV Won’t Be Forgotten
November 02 2023 1:27 PM
PEPFAR in Peril: The Far-Right Wants to End the Lifesaving Global HIV Program
October 24 2023 1:52 PM
Plus Nov/Dec Issue: PEPFAR in Danger & Our Allies and Advocates of the Year
October 23 2023 11:53 AM
Trending stories
Most Recent
Recommended Stories for You
HIV Plus Editors
Editor
Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.
Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.